Skip to main content
Equibles
REGN logo

REGN · Regeneron Pharmaceuticals, Inc. · Documents

Track REGN — free

Use REGN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research REGN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$955.47 +4.28 (+0.45%) At close · Nov 13 Play latest call Q3 2026 earnings call transcript
S&P 500 member Nasdaq-100 member Russell 1000 member Rebalance outlook locked
Market Cap
$98.84B
Shares
103.45M
Volume · Nov 13 1.17M Avg daily vol (3M) 792.82K

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

2024
Aug 1
Quarterly report 10-Q FY2024 Q2, ended Jun 30
Quarterly report for FY2024 Q2
Revenue $3.55B ▲ 12.3% Net income $1.43B ▲ 47.9% Diluted EPS $12.41 ▲ 46.0%
May 2
Quarterly report 10-Q FY2024 Q1, ended Mar 31
Quarterly report for FY2024 Q1
Revenue $3.15B ▼ 0.5% Net income $722M ▼ 11.7% Diluted EPS $6.27 ▼ 12.6%
Feb 5
Annual report 10-K FY2023, ended Dec 31
Annual report for FY2023
Revenue $13.12B ▲ 7.8% Net income $3.95B ▼ 8.9% Diluted EPS $34.77 ▼ 9.0%
2023
Nov 2
Quarterly report 10-Q FY2023 Q3, ended Sep 30
Quarterly report for FY2023 Q3
Revenue $3.36B ▲ 14.5% Net income $1.01B ▼ 23.4% Diluted EPS $8.89 ▼ 23.8%
Aug 3
Quarterly report 10-Q FY2023 Q2, ended Jun 30
Quarterly report for FY2023 Q2
Revenue $3.16B ▲ 10.5% Net income $968.4M ▲ 13.6% Diluted EPS $8.50 ▲ 13.8%
May 4
Quarterly report 10-Q FY2023 Q1, ended Mar 31
Quarterly report for FY2023 Q1
Revenue $3.16B ▲ 6.6% Net income $817.8M ▼ 16.0% Diluted EPS $7.17 ▼ 16.7%
Feb 6
Annual report 10-K FY2022, ended Dec 31
Annual report for FY2022
Revenue $12.17B ▼ 24.3% Net income $4.34B ▼ 46.3% Diluted EPS $38.22 ▼ 46.9%
2022
Nov 3
Quarterly report 10-Q FY2022 Q3, ended Sep 30
Quarterly report for FY2022 Q3
Revenue $2.94B ▼ 15.0% Net income $1.32B ▼ 19.4% Diluted EPS $11.66 ▼ 18.6%
Showing 51–100 of 166 documents
Key facts CIK 872589 CUSIP 75886F107 13F (30d) 1142 filings 1071 filers Visit website Investor relations